Vaxxas
Vaccines · Health Care
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Brandon CapitalVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Vaxxas Appoints Veteran Vaccine Leader to Board as Company Advances Needle-Free Vaccine Patch Towards Market
Seasoned global pharmaceutical executive, Mr Brent MacGregor, joins Vaxxas Board to accelerate self-administered HD-MAP vaccines for global use;SPRIM Global Investment's Co-Founder and Managing Partner, Mr Michael Shleifer appointed Board Observer followi
Read more
Report
Vaxxas: A$90 Million Secured For Commercializing Needle-Free Vaccination Delivery Technology
Vaxxas, a biotechnology company developing the high-density microarray patch (HD-MAP) for needle-free vaccine delivery, has secured approximately $90 million in its latest financing round. This funding, one of the largest in Australia for a private biotec
Read more
Report
Vaxxas secures A$90 million in funding to commercialiseneedle-free vaccination delivery technology
Total equity and debt raising of $90 million provides runway to 2H 2027Strong support from existing and new investors including SPRIM Global InvestmentsFunds will be used to scale-up production of needle-free vaccination delivery technologyFounding CEO Da
Read more
Report
Vaxxas and CEPI Advance US$4.8 million (AU$7.2 million) Program for Needle-Free Thermostable mRNA Vaccines
Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that CEPI...
Read more
Report
Vaxxas Awarded US$3.67 million (AU$5.4 million) from global charitable foundation, Wellcome, for Human Clinical Study of Typhoid Vaccination using Needle-Free Vaccine Patch
Read more
Report
Report
Vaxxas gets $20M for vaccine that can be worn as a patch
A Cambridge startup called Vaxxas that's developing vaccines are worn as patches just raised a $20 million Series B. The funding will be used to bring its Nanopatch platform to clinical trial, and to flesh out its pipeline of needle-free vaccines.
Read more
Report
Show more news